SCHEMBL1008554

SCHEMBL1008554

CCOc1ccc(F)c(O)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.42
FGFR2 P21802 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
KDM1A O60341 2/20 0.39
ALDH1A1 P00352 3/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ATM Q13315 1/20 0.37
PDE4A P27815 3/20 0.36
PDE4B Q07343 3/20 0.36
PDE4C Q08493 3/20 0.36
PDE4D Q08499 3/20 0.36
TUBB1 Q9H4B7 1/20 0.36
NPC1 O15118 1/20 0.36
USP2 O75604 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24240291 0.83 L3MBTL1 (0.47) L3MBTL1FGFR2HPGDKDM1AALDH1A1
SCHEMBL17527769 0.82 L3MBTL1 (0.48) L3MBTL1FGFR2HPGDTSHRKDM1A
SCHEMBL24445857 0.82 MRGPRX4 (0.40) L3MBTL1HPGDTSHRALDH1A1HTT
SCHEMBL17997262 0.81 TSHR (0.39) L3MBTL1HPGDTSHRCYP1A2CYP2D6
SCHEMBL423475 0.79 ALDH1A1 (0.46) L3MBTL1HPGDKDM1AALDH1A1CYP1A2
SCHEMBL28038952 0.79 ALDH1A1 (0.46) L3MBTL1HPGDKDM1AALDH1A1CYP1A2
SCHEMBL23939751 0.78 L3MBTL1 (0.41) L3MBTL1HPGDTSHRKDM1AALDH1A1
SCHEMBL17181453 0.78 FGFR2 (0.43) L3MBTL1FGFR2ALDH1A1
SCHEMBL4405598 0.78 ALDH1A1 (0.45) L3MBTL1FGFR2HPGDTSHRKDM1A
SCHEMBL13125478 0.78 L3MBTL1 (0.43) L3MBTL1FGFR2HPGDKDM1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 L3MBTL1 4431/4885FGFR2 3031/4885HPGD 472/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK L3MBTL1 4364/4885FGFR2 3646/4885HPGD 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.